4.5 Review

PKC and PKN in heart disease

期刊

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
卷 128, 期 -, 页码 212-226

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2019.01.029

关键词

PKC; PKN; Kinase; Cardiomyopathy; Phosphorylation

资金

  1. NIH [HL128457, HL107744, 20180199]
  2. Swedish Hjart-Lungfonden [HL128457, HL107744, 20180199]
  3. British Heart Foundation [RE/13/2/30182]
  4. MRC [MR/R017050/1]
  5. European Commission [656636]
  6. American Heart Association [17POST33661136]
  7. Marie Curie Actions (MSCA) [656636] Funding Source: Marie Curie Actions (MSCA)
  8. Swedish Heart-Lung Foundation [20180199] Funding Source: Swedish Heart-Lung Foundation
  9. MRC [MR/R017050/1] Funding Source: UKRI

向作者/读者索取更多资源

The protein kinase C (PKC) and closely related protein kinase N (PKN) families of serine/threonine protein kinases play crucial cellular roles. Both kinases belong to the AGC subfamily of protein kinases that also include the CAMP dependent protein kinase (PKA), protein kinase B (PKB/AKT), protein kinase G (PKG) and the ribosomal protein S6 kinase (S6K). Involvement of PKC family members in heart disease has been well documented over the years, as their activity and levels are mis-regulated in several pathological heart conditions, such as ischemia, diabetic cardiomyopathy, as well as hypertrophic or dilated cardiomyopathy. This review focuses on the regulation of PKCs and PKNs in different pathological heart conditions and on the influences that PKC/PKN activation has on several physiological processes. In addition, we discuss mechanisms by which PKCs and the closely related PKNs are activated and turned-off in hearts, how they regulate cardiac specific downstream targets and pathways, and how their inhibition by small molecules is explored as new therapeutic target to treat cardiomyopathies and heart failure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据